.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,951,717

« Back to Dashboard

Details for Patent: 6,951,717

Title: Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
Abstract:Parainfluenza virus types 1 to 4 (PIV1 to PIV4) are important human pathogens that cause upper and lower respiratory tract infections, particularly in infants and children. The claimed invention is directed toward novel methods for the inhibition of parainfluenza virus transmission to a cell involving the administration of synthetic peptide fusion inhibitors. These inhibitors are derived from the parainfluenza virus and vary in length between 16 to 39 amino acids. The peptides were identified by screening for the presence of fusion inhibitory motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) within the parainfluenza virus genome. A number of peptides were identified and their fusion inhibitory activities ascertained. These peptides should provide useful antiviral agents.
Inventor(s): Barney; Shawn O'Lin (Cary, NC), Lambert; Dennis Michael (Cary, NC), Petteway; Stephen Robert (Cary, NC)
Assignee: Trimeris, Inc. (Durham, NC)
Filing Date:Jun 07, 1995
Application Number:08/484,741
Claims:1. A method for the inhibition of transmission of a parainfluenza virus to a cell, comprising contacting the cell with an effective concentration of an isolated peptide consisting of an amino acid sequence of a 16 to 39 amino acid residue region of a parainfluenza virus protein for an effective period of time; wherein said region is identified by an ALLMOTI15, 107x178x4, or PLZIP sequence search motif; wherein said peptide further comprises an amino terminal X, and a carboxy terminal Z in which: X comprises an amino group, an acetyl group, a 9-fluorenylmethoxy-carbonyl group, a hydrophobic group, or a macromolecular carrier group; and Z comprises a carboxyl group, an amido group, a hydrophobic group, or a macromolecular carrier group;

and wherein fusion of the virus to the cell is inhibited.

2. A method for the inhibition of transmission of parainfluenza virus to a cell, comprising contacting the cell with an effective concentration of a peptide for an effective period of time; wherein the peptide has the formula: X-TLNNSVALDPIDISIELNKAKSDLEESKEWIRRSN-Z (SEQ ID NO. 33); X-LNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQ-Z (SEQ ID NO. 34); X-NNSVALDPIDISIELNKAKSDLEESKEWIRRSNQK-Z (SEQ ID NO. 35); X-NSVALDPIDISIELNKAKSDLEESKEWIRRSNQKL-Z (SEQ ID NO. 36); X-SVALDPIDISIELNKAKSDLEESKEWIRRSNQKLD-Z (SEQ ID NO. 37); X-VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDS-Z (SEQ ID NO. 38); X-ALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI-Z (SEQ ID NO. 39); X-LDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIG-Z (SEQ ID NO. 40); X-DPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGN-Z (SEQ ID NO. 41); X-PIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNW-Z (SEQ ID NO. 42); X-IDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWH-Z (SEQ ID NO. 43); X-DISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQ-Z (SEQ ID NO. 44); X-ISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQS-Z (SEQ ID NO. 45); X-SIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSS-Z (SEQ ID NO. 46); X-IELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSST-Z (SEQ ID NO. 47); X-ELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT-Z (SEQ ID NO. 48); X-TAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQS-Z (SEQ ID NO. 49); X-AVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSI-Z (SEQ ID NO. 50); X-LVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNL-Z (SEQ ID NO. 51); X-VEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLI-Z (SEQ ID NO. 52); X-EAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIV-Z (SEQ ID NO. 53); X-AKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVA-Z (SEQ ID NO. 54); X-KQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAI-Z (SEQ ID NO. 55); X-QARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIK-Z (SEQ ID NO. 56); X-ARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKS-Z (SEQ ID NO. 57); X-RSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSV-Z (SEQ ID NO. 58); X-SDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQ-Z (SEQ ID NO. 59); X-KLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVN-Z (SEQ ID NO. 60); X-LKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNK-Z (SEQ ID NO. 61); or X-AIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIV-Z (SEQ ID NO. 62), in which: amino acid residues are presented by the single-letter code; X comprises an amino group, an acetyl group, a 9-fluorenylmethoxy-carbonyl group, a hydrophobic group, or a macromolecular carrier group; Z comprises a carboxyl group, an amido group, a hydrophobic group, or a macromolecular carrier group;

and wherein fusion of the virus to the cell is inhibited.

3. The method of claim 2, wherein the peptide has the formula: X-IDISIELNKAKSDLEESKEWIRRSNQKLDSIGNWH-Z (SEQ ID NO. 43).

4. The method of claim 2, wherein the peptide has the formula: X-TLNNSVALDPIDISIELNKAKSDLEESKEWIRRSN-Z (SEQ ID NO. 33).

5. The method of claim 2, wherein the peptide has the formula: X-LNNSVALDPIDISIELNKAKSDLEESKEWIRRSNQ-Z (SEQ ID NO. 34).

6. The method of claim 2, wherein the peptide has the formula: X-NNSVALDPIDISIELNKAKSDLEESKEWIRRSNQK-Z (SEQ ID NO. 35).

7. The method of claim 2, wherein the peptide has the formula: X-NSVALDPIDISIELNKAKSDLEESKEWIRRSNQKL-Z (SEQ ID NO. 36).

8. The method of claim 2, wherein the peptide has the formula: X-SVALDPIDISIELNKAKSDLEESKEWIRRSNQKLD-Z (SEQ ID NO. 37).

9. The method of claim 2, wherein the peptide has the formula: X-VALDPIDISIELNKAKSDLEESKEWIRRSNQKLDS-Z (SEQ ID NO. 38).

10. The method of claim 2, wherein the peptide has the formula: X-ALDPIDISIELNKAKSDLEESKEWIRRSNQKLDSI-Z (SEQ ID NO. 39).

11. The method of claim 2, wherein the peptide has the formula: X-LDPIDISIELNKAKSDLEESKEWIRRSNQKLDSIG-Z (SEQ ID NO. 40).

12. The method of claim 2, wherein the peptide has the formula: X-DPIDISIELNKAKSDLEESKEWIRRSNQKLDSIGN-Z (SEQ ID NO. 41).

13. The method of claim 2, wherein the peptide has the formula: X-PIDISIELNKAKSDLEESKEWIRRSNQKLDSIGNW-Z (SEQ ID NO. 42).

14. The method of claim 2, wherein the peptide has the formula: X-DISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQ-Z (SEQ ID NO. 44).

15. The method of claim 2, wherein the peptide has the formula: X-ISIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQS-Z (SEQ ID NO. 45).

16. The method of claim 2, wherein the peptide has the formula: X-SIELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSS-Z (SEQ ID NO. 46).

17. The method of claim 2, wherein the peptide has the formula: X-IELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSST-Z (SEQ ID NO. 47).

18. The method of claim 2, wherein the peptide has the formula: X-ELNKAKSDLEESKEWIRRSNQKLDSIGNWHQSSTT-Z (SEQ ID NO. 48).

19. The method of claim 2, wherein the peptide has the formula: X-TAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQS-Z (SEQ ID NO. 49).

20. The method of claim 2, wherein the peptide has the formula: X-AVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSI-Z (SEQ ID NO. 50).

21. The method of claim 2, wherein the peptide has the formula: X-LVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNL-Z (SEQ ID NO. 51).

22. The method of claim 2, wherein the peptide has the formula: X-VEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLI-Z (SEQ ID NO. 52).

23. The method of claim 2, wherein the peptide has the formula: X-EAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIV-Z (SEQ ID NO. 53).

24. The method of claim 2, wherein the peptide has the formula: X-AKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVA-Z (SEQ ID NO. 54).

25. The method of claim 2, wherein the peptide has the formula: X-KQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAI-Z (SEQ ID NO. 55).

26. The method of claim 2, wherein the peptide has the formula: X-QARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIK-Z (SEQ ID NO. 56).

27. The method of claim 2, wherein the peptide has the formula: X-ARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKS-Z (SEQ ID NO. 57).

28. The method of claim 2, wherein the peptide has the formula: X-RSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSV-Z (SEQ ID NO. 58).

29. The method of claim 2, wherein the peptide has the formula: X-SDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQ-Z (SEQ ID NO. 59).

30. The method of claim 2, wherein the peptide has the formula: X-KLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVN-Z (SEQ ID NO. 60).

31. The method of claim 2, wherein the peptide has the formula: X-LKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNK-Z (SEQ ID NO. 61).

32. The method of claim 2, wherein the peptide has the formula: X-AIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIV-Z (SEQ ID NO. 62).

33. The method of claim 1, wherein the region of the parainfluenza virus protein is a region of 28 amino acid residues identified by the ALLMOTI5 motif.

34. The method of claim 1, wherein the region of the parainfluenza virus protein is a region of 35 amino acid residues identified by the ALLMOTI5 motif.

35. The method of claim 1, wherein the region of the parainfluenza virus protein is a region of 28 amino acid residues identified by the 107x178x4 motif.

36. The method of claim 1, wherein the region of the parainfluenza virus protein is a region of 35 amino acid residues identified by the 107x178x4 motif.

37. The method of claim 1, wherein the region of the parainfluenza virus protein is identified by a PLZIP motif.

38. The method of claim 1 wherein X is an acetyl group.

39. The method of claim 1 wherein Z is an amido group.

40. The method of claim 1 wherein X is an acetyl group; and Z is an amido group.

41. The method of claim 1 wherein X is a macromolecular carrier group.

42. The method of claim 41 wherein the macromolecular carrier group X is a peptide group.

43. The method of claim 42 wherein the peptide group is 2 to 50 parainfluenza virus protein amino acid residues amino to the region of the parainfluenza virus protein identified by the ALLMOTI5, 107x178x4 or PLZIP sequence search motif.

44. The method of claim 1 wherein Z is a macromolecular carrier group.

45. The method of claim 44 wherein the macromolecular carrier group Z is a peptide group.

46. The method of claim 45 wherein the peptide group is about 2 to about 50 parainfluenza virus protein amino acid residues carboxy to the region of the parainfluenza virus protein identified by the ALLMOTI5, 107x178x4 or PLZIP sequence search motif.

47. The method of claim 46 wherein X is a macromolecular carrier group, said macromolecular carrier group X being a peptide group of 2 to 50 parainfluenza virus protein amino acid residues amino to the region of the parainfluenza virus protein identified by the ALLMOTI5, 107x 178x4 or PLZIP sequence search motif.

48. The method of claim 2 wherein X is an acetyl group.

49. The method of claim 2 wherein Z is an amido group.

50. The method of claim 2 wherein X is an acetyl group; and Z is an amido group.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc